Redchenko, I., Cappuccini, F., Pollock, E., Bryant, R., Carter, L., Verrill, C., . . . Hill, A. (2018). VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer. American Society of Clinical Oncology.
Chicago Style (17th ed.) CitationRedchenko, I., et al. VANCE: First-in-human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine in Low and Intermediate Risk Prostate Cancer. American Society of Clinical Oncology, 2018.
MLA (9th ed.) CitationRedchenko, I., et al. VANCE: First-in-human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine in Low and Intermediate Risk Prostate Cancer. American Society of Clinical Oncology, 2018.
Warning: These citations may not always be 100% accurate.